140 related articles for article (PubMed ID: 34989825)
21. Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies.
Schmidt N; Hess V; Zumbrunn T; Rothermundt C; Bongartz G; Potthast S
Eur Radiol; 2013 Mar; 23(3):632-9. PubMed ID: 22918564
[TBL] [Abstract][Full Text] [Related]
22. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
[TBL] [Abstract][Full Text] [Related]
23. Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria.
Goebel J; Hoischen J; Gramsch C; Schemuth HP; Hoffmann AC; Umutlu L; Nassenstein K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2527-2533. PubMed ID: 28825135
[TBL] [Abstract][Full Text] [Related]
24. [Value of dual-energy CT-based volumetric iodine-uptake in the evaluation of chemotherapy efficacy in advanced gastric cancer].
Chen LF; Fu GZ; Huang DP; Man Y; Jin Y; Dong QT; Huang YB; Chen YC; Wang HQ
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Oct; 22(10):977-983. PubMed ID: 31630497
[No Abstract] [Full Text] [Related]
25. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST.
de Mestier L; Resche-Rigon M; Dromain C; Lamarca A; La Salvia A; de Baker L; Fehrenbach U; Pusceddu S; Colao A; Borbath I; de Haas R; Rinzivillo M; Zerbi A; Funicelli L; de Herder WW; Selberherr A; Wagner AD; Manoharan P; De Cima A; Lybaert W; Jann H; Prinzi N; Faggiano A; Annet L; Walenkamp A; Panzuto F; Pedicini V; Pitoni MG; Siebenhuener A; Mayerhoefer ME; Ruszniewski P; Vullierme MP
J Neuroendocrinol; 2023 Jun; 35(6):e13311. PubMed ID: 37345276
[TBL] [Abstract][Full Text] [Related]
26. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
[TBL] [Abstract][Full Text] [Related]
27. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy.
Huizing DMV; Aalbersberg EA; Versleijen MWJ; Tesselaar MET; Walraven I; Lahaye MJ; de Wit-van der Veen BJ; Stokkel MPM
Cancer Imaging; 2020 Aug; 20(1):57. PubMed ID: 32778165
[TBL] [Abstract][Full Text] [Related]
28. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
[TBL] [Abstract][Full Text] [Related]
29. Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres.
Shady W; Sotirchos VS; Do RK; Pandit-Taskar N; Carrasquillo JA; Gonen M; Sofocleous CT
AJR Am J Roentgenol; 2016 Sep; 207(3):661-70. PubMed ID: 27384594
[TBL] [Abstract][Full Text] [Related]
30. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
[TBL] [Abstract][Full Text] [Related]
31. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Haanen JB; Boven E
Br J Cancer; 2010 Mar; 102(5):803-9. PubMed ID: 20145618
[TBL] [Abstract][Full Text] [Related]
32. The Choi response criteria for inferior vena cava tumor thrombus in renal cell carcinoma treated with targeted therapy.
Kwon T; Lee JL; Kim JK; You D; Jeong IG; Song C; Ahn H; Kim CS; Hong JH
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1751-8. PubMed ID: 24841738
[TBL] [Abstract][Full Text] [Related]
33. We should desist using RECIST, at least in GIST.
Benjamin RS; Choi H; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Charnsangavej C
J Clin Oncol; 2007 May; 25(13):1760-4. PubMed ID: 17470866
[TBL] [Abstract][Full Text] [Related]
34. Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma.
Weng Z; Ertle J; Zheng S; Lauenstein T; Mueller S; Bockisch A; Gerken G; Yang D; Schlaak JF
Oncol Lett; 2013 Dec; 6(6):1707-1712. PubMed ID: 24260066
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of
Zidan L; Iravani A; Oleinikov K; Ben-Haim S; Gross DJ; Meirovitz A; Maimon O; Akhurst T; Michael M; Hicks RJ; Grozinsky-Glasberg S; Kong G
J Nucl Med; 2022 Feb; 63(2):218-225. PubMed ID: 34049983
[TBL] [Abstract][Full Text] [Related]
36. Correlation of radiological and histopathological response after neoadjuvant radiotherapy in soft tissue sarcoma.
Reijers SJM; Gennaro N; Bruining A; van Boven H; Snaebjornsson P; Bekers EM; van Coevorden F; Scholten AN; Schrage Y; van der Graaf WTA; Haas RLM; van Houdt WJ
Acta Oncol; 2023 Jan; 62(1):25-32. PubMed ID: 36637511
[TBL] [Abstract][Full Text] [Related]
37. Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Oh ST; Kim JG; Choi MH; Lee MA
Cancer Res Treat; 2018 Jan; 50(1):283-292. PubMed ID: 28494536
[TBL] [Abstract][Full Text] [Related]
38. Different Radiological Criteria for Early Tumor Response Evaluation in Patients With Unresectable Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody Plus Bevacizumab.
Xu Y; Yang Y; Li L; Zhou A; Zhang H; Ye F; Zhang W; Zhao H; Zhao X
Front Oncol; 2022; 12():848129. PubMed ID: 35515116
[TBL] [Abstract][Full Text] [Related]
39. Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC).
Gupta S; Kang HC; Sun J; Matrana MR; Tannir NM; Choi H
Abdom Radiol (NY); 2020 Jun; 45(6):1872-1882. PubMed ID: 31822966
[TBL] [Abstract][Full Text] [Related]
40. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
Sonpavde G; Pond GR; Templeton AJ; Fandi A; Tombal B; Rosenthal M; Armstrong AJ; Petrylak DP
Eur Urol; 2016 Jun; 69(6):980-3. PubMed ID: 26497922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]